Development of imidazolone based angiotensin II receptor type I inhibitor small molecule as a chemotherapeutic agent for cell cycle inhibition

References

• Azmi AS, Mohammad RM. 2009. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol. 218(1):13–21.
   PubMed Web of Science ®Google Scholar
• Barreca M, Spanò V, Montalbano A, Cueto M, Díaz marrero AR, Deniz I, Erdoğan A, Lukić Bilela L, Moulin C, Taffin-de-givenchy E, et al. 2020. Marine anticancer agents: an overview with a particular focus on their chemical classes. Mar Drugs. 18(12):619.
   Web of Science ®Google Scholar
• Bataller R, Ginès P, Nicolás JM, Görbig MN, Garcia-ramallo E, Gasull X, Bosch J, Arroyo V, Rodés J. 2000. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 118(6):1149–1156.
   PubMed Web of Science ®Google Scholar
• Bauer JH, Reams GP. 1995. The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med. 155(13):1361–1368.
   Google Scholar
• Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L, Dong X. 2013. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 328(2):318–324.
   PubMed Web of Science ®Google Scholar
• Debatin K-M. 2000. Activation of apoptosis pathways by anticancer treatment. Toxicol Lett. 112-113:41–48.
   PubMed Web of Science ®Google Scholar
• De Paepe B, Verstraeten VM, De Potter CR, Bullock GR. 2002. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol. 117(1):13–19.
   Web of Science ®Google Scholar
• Deshayes F, Nahmias C. 2005. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 16(7):293–299.
   PubMed Web of Science ®Google Scholar
• Du N, Feng J, Hu LJ, Sun X, Sun HB, Zhao Y, Yang YP, Ren H. 2012. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Oncol Rep. 27:1893–1903.
   PubMed Web of Science ®Google Scholar
• Durdagi S, Aksoydan B, Erol I, Kantarcioglu I, Ergun Y, Bulut G, Acar M, Avsar T, Liapakis G, Karageorgos V, et al. 2018. Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation. Eur J Med Chem. 145:273–290.
   Web of Science ®Google Scholar
• Evan GI, Vousden KH. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature. 411(6835):342–348.
   PubMed Web of Science ®Google Scholar
• Fogarty DJ, Sánchez-gómez MV, Matute C. 2002. Multiple angiotensin receptor subtypes in normal and tumor astrocytes in vitro. Glia. 39(3):304–313.
   Web of Science ®Google Scholar
• Fozooni S, Khoshdast H, Hassani H, Hamidian H. 2017. Synthesis of oxazolone and imidazolone derivatives in presence of H2O2 promoted fly ash as a novel and efficient catalyst. J Sci Islamic Repub Iran. 28:221–230.
   Google Scholar
• Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. 2006. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 49(21):6177–6196.
   PubMed Web of Science ®Google Scholar
• Fujihara S, Morishita A, Ogawa K, Tadokoro T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H, Masaki T. 2017. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo. Oncotarget. 8(5):8536–8549.
   Google Scholar
• Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. 2001. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 495(3):197–200.
   Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell. 144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Lupyan D, Dahlgren MK, Knight JL. 2016. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput. 12(1):281–296.
   PubMed Web of Science ®Google Scholar
• Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA. 2004. A hierarchical approach to all-atom protein loop prediction. Proteins Struct Funct Bioinf. 55(2):351–367.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. 1996. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56:816–825.
   PubMed Web of Science ®Google Scholar
• Juillerat-Jeanneret L, Celerier J, Chapuis bernasconi C, Nguyen G, Wostl W, Maerki HP, Janzer RC, Corvol P, Gasc JM. 2004. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer. 90(5):1059–1068.
   Web of Science ®Google Scholar
• Kastan MB, Bartek J. 2004. Cell-cycle checkpoints and cancer. Nature. 432(7015):316–323.
   PubMed Web of Science ®Google Scholar
• Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M. 2007. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate. 67(1):41–49.
   PubMed Web of Science ®Google Scholar
• Koyama N, Nishida Y, Ishii T, Yoshida T, Furukawa Y, Narahara H. 2014. Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS One. 9(3):e93050.
   Web of Science ®Google Scholar
• Kozako T, Soeda S, Yoshimitsu M, Arima N, Kuroki A, Hirata S, Tanaka H, Imakyure O, Tone N, Honda S, et al. 2016. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells. FEBS Open Bio. 6(5):442–460.
   PubMed Web of Science ®Google Scholar
• Li Petri G, Spanò V, Spatola R, Holl R, Raimondi MV, Barraja P, Montalbano A. 2020. Bioactive pyrrole-based compounds with target selectivity. Eur J Med Chem. 208:112783–112783.
   Web of Science ®Google Scholar
• Liu W-B, Wang X-P, Wu K, Zhang R-L. 2005. Effects of angiotensin II receptor antagonist, losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells. World J Gastroenterol. 11(41):6489–6494.
   Web of Science ®Google Scholar
• Mavromoustakos T, Agelis G, Durdagi S. 2013. AT1 antagonists: a patent review (2008–2012). Expert Opin Ther Pat. 23(11):1483–1494.
   Web of Science ®Google Scholar
• Raffa D, Maggio B, Cascioferro S, Raimondi MV, Daidone G, Plescia S, Schillaci D, Cusimano MG, Titone L, Colomba C. 2009. N-(indazolyl) benzamido derivatives as CDK1 inhibitors: design, synthesis, biological activity, and molecular docking studies. Arch Pharm. 342(5):265–273.
   Web of Science ®Google Scholar
• Ray PE, Aguilera G, Kopp JB, Horikoshi S, Klotman PE. 1991. Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells. Kidney Int. 40(4):764–771.
   Web of Science ®Google Scholar
• Sahin Z, Biltekin SN, Yurttas L, Berk B, Özhan Y, Sipahi H, Gao ZG, Jacobson KA, Demirayak Ş. 2021. Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: adenosine receptor binding and potent PDE4 inhibition. Eur J Med Chem. 212:113125.
   PubMed Web of Science ®Google Scholar
• Sancar A, Lindsey-boltz LA, Unsal-kaçmaz K, Linn S. 2004. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73(1):39–85.
   PubMed Web of Science ®Google Scholar
• Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M. 2007. Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des. 21(12):681–691.
   PubMed Web of Science ®Google Scholar
• Smith MT, Woodruff TM, Wyse BD, Muralidharan A, Walther T. 2013. A small molecule angiotensin II type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Med. 14(10):1557–1568.
   PubMed Web of Science ®Google Scholar
• Smith MT, Wyse BD, Edwards SR. 2013. Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med. 14(5):692–705.
   PubMed Web of Science ®Google Scholar
• Spanò V, Frasson I, Giallombardo D, Doria F, Parrino B, Carbone A, Montalbano A, Nadai M, Diana P, Cirrincione G, et al. 2016. Synthesis and antiproliferative mechanism of action of pyrrolo[3',2':6,7] cyclohepta[1,2-d]pyrimidin-2-amines as singlet oxygen photosensitizers. Eur J Med Chem. 123:447–461.
   Web of Science ®Google Scholar
• Spanò V, Pennati M, Parrino B, Carbone A, Montalbano A, Cilibrasi V, Zuco V, Lopergolo A, Cominetti D, Diana P, et al. 2016. Preclinical activity of New [1,2]oxazolo[5,4-e]isoindole derivatives in diffuse Malignant peritoneal mesothelioma. J Med Chem. 59(15):7223–7238.
   Web of Science ®Google Scholar
• Spanò V, Rocca R, Barreca M, Giallombardo D, Montalbano A, Carbone A, Raimondi MV, Gaudio E, Bortolozzi R, Bai R, et al. 2020. Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles, a new class of antimitotic agents active against multiple malignant cell types. J Med Chem. 63(20):12023–12042.
   Web of Science ®Google Scholar
• Swift LH, Golsteyn RM. 2014. Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells. Int J Mol Sci. 15(3):3403–3431.
   PubMed Web of Science ®Google Scholar
• Weaver BA. 2014. How taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25(18):2677–2681.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. 2009. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 9(1):28–39.
   PubMed Web of Science ®Google Scholar